ClinConnect ClinConnect Logo
Search / Trial NCT03862287

Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Mar 1, 2019

Trial Information

Current as of August 11, 2025

Unknown status

Keywords

ClinConnect Summary

Ever since the introduction of Spinal anesthesia in 1898 by the German surgeon August Bier, the approach gained wide acceptance by the anesthesia community 1. Since that time, the technique has evolved to accommodate a wide variety of surgical procedures, making it one of the most common regional anesthesia modalities used. The advancement of the anesthesia field has led to the advancement of the technique it self, specially the drugs used in it.

A wide range of local anesthetics has been introduced after the initial successful intrathecal use of cocaine. Starting with amylocaine, and late...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ASA I-III male and female patients aged between 18 to 80 years old, who will receive spinal anesthesia for surgeries lasting less than one hour.
  • Exclusion Criteria:
  • Patients younger than 18 years old.
  • ASA physical status \>3.
  • Immunosuppression or high risk of infection.
  • Contraindications to receiving spinal anesthesia (e.g. coagulation impairment).
  • Patients with psychosis
  • Patients with preexisting back pain.
  • Patients with cognitive impairment
  • Allergies to local anesthetics, analgesics or any medication used in the study.
  • Patients with chronic regular opioid usage
  • Presence of preexisting neurological symptoms.

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Montreal, Quebec, Canada

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials